

Anna Tesei, MSc, PhD

Present Position: Head of Radiobiology and Drug Discovery Unit at IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola (FC), Italy.

Work address: Department of Medical Oncology and Oncohaematology, Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" – IRST, via P. Maroncelli 40, 47014 Meldola (FC) Italy

Academic

Qualification: 1993: graduated in Biological Science at the University of Bologna.
1998: Specialized in Biochemistry and Clinical Chemistry at the Medicine Faculty of the University of Parma
2006: PhD in Pharmacology and Toxicology at the University of Bologna
2011-2015: CNR associated researcher at ISOF-CNR Institute of Bologna

Patents: **US 20120041046 A1**: Non-steroidal compounds for androgen receptor modulation
US 20110275829 A1: Androgen receptor modulating compounds, preparation and uses thereof

Awards: **2019**: Scientific Coordinator of a Research Unit for the project "CUBIBOX" -Bando POR Emilia-Romagna.
2016: winner of Ministerial Health project "CONTO CAPITALE 2015"
2006-2008: Scientific Coordinator of a Research Unit of Ministerial Health "Ricerca Finalizzata project" - F.S.N. 200 Conv.n.87
2007-2010: Head of a Research Unit in the Programma Integrato Oncologia project (P.I.O., Conv. N.RO Strategic 9/07 Ministerial Health project)

Research Activity:

Dr. Tesei's work has focused on the search for innovative anti-cancer therapeutic approaches in the fields of pharmacology and radiobiology, and she has developed preclinical models closely mimicking in vivo tumor conditions on which to test new molecules or innovative radiotherapy fractionation schedules, alone or alone or in combination with each other. She has also researched into cancer stem cell isolation, stem cell self-renewal and stemness maintenance. She has long-standing research experience in the following areas: 3D cell cultures, radio- and drug-sensitivity and resistance pathways, DNA repair mechanisms, mechanisms of action of antineoplastic drugs, hormone therapy, targeted therapy, tumor animal models (Zebrafish models). Within the context of a multidisciplinary research collaboration with the Institute of Organic Chemistry and Photoreactivity (Italian National Research Council, CNR), Dr. Tesei is a co-inventor of two USA-granted patents pertaining to synthesis methodology of novel SARMs that are effective against castrate-resistant prostate cancer models.

She is author and co-author of over 80 scientific articles on peer reviewed journal. She takes part also in several Ministerial Health project as researcher and scientific referent.

As head of a research team, she is frequently involved in student mentoring activities and acts as thesis co-advisor for undergraduates and PhD and Masters students.

References

- Zanoni M, Sarti AC, Zamagni A, Cortesi M, Pignatta S, Arienti C, Tebaldi M, Sarnelli A, Romeo A, Bartolini D, Tosatto L, Adinolfi E, **Tesei A***, Di Virgilio F. Irradiation causes senescence, ATP release, and P2X7 receptor isoform switch in glioblastoma. *Cell Death Dis.* 2022 Jan 24;13(1):80.
- Vultaggio-Poma V, Falzoni S, Chiozzi P, Sarti AC, Adinolfi E, Giuliani AL, Sánchez-Melgar A, Boldrini P, Zanoni M, **Tesei A**, Pinton P, Di Virgilio F. Extracellular ATP is increased by release of ATP-loaded microparticles triggered by nutrient deprivation. *Theranostics.* 2022 Jan 1;12(2):859-874.
- Pegoraro A, De Marchi E, Ferracin M, Orioli E, Zanoni M, Bassi C, **Tesei A**, Capece M, Dika E, Negrini M, Di Virgilio F, Adinolfi E. P2X7 receptor favors melanoma metastasis and causes the release of miRNA-containing exosomes and microvesicles from cancer cells. *Cell Death Dis.* 2021 Nov 16;12(12):1088
- Peirsman A, Blondeel E, Audenaert D, Krisztina B, Carragher N, De Tullio P, De Vlieghere E, Dedeyne S, Depypere H, Dmitriev R, Dolznig H, Gespach C, Goossens V, Heino J, Hendrix A, Horvath P, Kunz-Schughart L, Maes S, Mangodt C, Dangles-Marie V, Oliveira M, Pampaloni F, Piccinini F, Robbins S, Steigemann P, Takayama S, **Tesei A**, Tulkens J, Van Waeyenberge M, Wagemans G, Blondeel P, Ahmed T, Anckaert J, Boterberg T, Castellani G, Castro F, Dawson J, Diosdi A, Fischer S, Mestdagh P, Michlíková S, Pinheiro C, Siljamäki E, Sys G, Vandesompele Jo, Weindorfer C, Yigit N, Zablowsky N, Zanoni M, Rahn J, de Wever O. MISpheroid: a knowledgebase and transparency tool for Minimal Information in Spheroid Identity. *Nature Methods, Nat Methods.* 2021 Nov;18(11):1294-1303.
- Arpa D, Parisi E, Ghigi G, Cortesi A, Longobardi P, Cenni P, Pieri M, Tontini L, Neri E, Micheletti S, Ghetti F, Monti M, Foca F, **Tesei A**, Arienti C, Sarnelli A, Martinelli G, Romeo A. Role of Hyperbaric Oxygenation Plus Hypofractionated Stereotactic Radiotherapy in Recurrent High-Grade Glioma. *Front Oncol.* 2021 Mar 30; 11:643469.
- Arienti C, Pignatta S, Zanoni M, Zamagni A, Cortesi M, Sarnelli A, Romeo A, Arpa D, Longobardi P, Bartolini D, Tosatto L, Naldini A, **Tesei A**. High-pressure oxygen rewires glucose metabolism of patient-derived glioblastoma cells and fuels inflammasome response. *Cancer Lett.* 2021 May 28; 506:152-166.
- De Santis I, Zanoni M, Arienti C, Bevilacqua A, **Tesei A**. Density Distribution Maps: A Novel Tool for Subcellular Distribution Analysis and Quantitative Biomedical Imaging. *Sensors (Basel)* 2021 Feb 2;21(3):1009.
- Tesei A**, Arienti C, Bossi G, Santi S, De Santis I, Bevilacqua A, Zanoni M, Pignatta S, Cortesi M, Zamagni A, Storci G, Bonafè M, Sarnelli A, Romeo A, Cavallo C, Bartolazzi A, Rossi S, Soriani A, Strigari L. TP53 drives abscopal effect by secretion of senescence-associated molecular signals in non-small cell lung cancer. *J Exp Clin Cancer Res.* 2021 Mar 5;40(1):89.
- Di Donato M, Zamagni A, Galasso G, Di Zazzo E, Giovannelli P, Barone MV, Zanoni M, Gunelli R, Costantini M, Auricchio F, Migliaccio A, **Tesei A***, Castoria G. The androgen receptor/filamin A complex as a target in prostate cancer microenvironment. *Cell Death Dis.* 2021 Mar 15;12(3):272.
- Tesei A** & Castoria G. Editoria: The Androgen Receptor in Breast Cancer. *Front. Endocrinol.* 2021 11:636480. doi: 10.3389/fendo.2020.636480
- Cortesi M, Zamagni A, Pignatta S, Zanoni M, Arienti C, Rossi D, Collina S, **Tesei A**. Pan-Sigma Receptor Modulator RC-106 Induces Terminal Unfolded Protein Response In In Vitro Pancreatic Cancer Model. *Int J Mol Sci.* 2020 Nov 27;21(23):9012.
- Zamagni A, Zanoni M, Cortesi M, Arienti C, Pignatta S, Naldini A, Sarnelli A, Romeo A, **Tesei A**. Investigating the Benefit of Combined Androgen Modulation and Hypofractionation in Prostate Cancer. *Int J Mol Sci.* 2020 Nov 10;21(22):E8447.
- Arpa D, Parisi E, Ghigi G, Savini A, Colangione SP, Tontini L, Pieri M, Foca F, Polico R, **Tesei A**, Sarnelli A, Romeo A. Re-irradiation of recurrent glioblastoma using helical TomoTherapy with simultaneous integrated boost: preliminary considerations of treatment efficacy. *Sci Rep.* 2020 Nov 9;10(1):19321
- Pignatta S, Cortesi M, Arienti C, Zanoni M, Cocchi C, Sarnelli A, Arpa D, Piccinini F, **Tesei A**. Effects of radiotherapy and short-term starvation combination on metastatic and non-tumor cell lines. *DNA Repair* 95 (2020) 1029-49.
- Listro R, Stotani S, Rossino G, Rui M, Malacrida A, Cavaletti G, Cortesi M, Arienti C, **Tesei A**, Rossi D, Giacomo MD, Miloso M, Collina S. Exploring the RC-106 Chemical Space: Design and Synthesis of Novel (E)-1-(3-Arylbut-2-en-1-yl)-4-(Substituted) Piperazine Derivatives as Potential Anticancer Agents. *Front Chem.* 2020 Jun 30; 8:495.
- Zanoni M, Cortesi M, Zamagni A, Arienti C, Pignatta S, **Tesei A**. Modeling neoplastic disease with spheroids and organoids. *J Hematol Oncol.* 2020 Jul 16; 13(1):97.

17. Zamagni A, Pasini A, Pirini F, Ravaoli S, Giordano E, **Tesei A**, Calistri D, Ulivi P, Fabbri F, Foca F, Delmonte A, Molinari C. CDKN1A upregulation and cisplatin-pemetrexed resistance in non-small cell lung cancer cells. *Int J Oncol*. 2020 Jun;56(6):1574-1584
18. Arienti C, Pignatta S, **Tesei A**. Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer. *Front Oncol*. 2019 Nov 26; 9:1308.
19. Zamagni A, Cortesi M, Zanoni M, **Tesei A**. Non-nuclear AR Signaling in Prostate Cancer. *Front. Chem.*, Nov26; 9:1308.
20. Zanoni M, Cortesi M, Zamagni A, **Tesei A**. The Role of Mesenchymal Stem Cells in Radiation-Induced Lung Fibrosis. *Int J Mol Sci*. 2019 Aug 8; 20(16). pii: E3876. doi: 10.3390/ijms20163876. Review.
21. Parisi E, Genestreti G, Sarnelli A, Ghigi G, Arpa D, Burgio MA, Gavelli G, Rossi A, Scarpi E, Monti M, **Tesei A**, Polico R, Romeo A. Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-up. *Radiat Oncol*. 2019 Jun 24; 14(1):112.
22. **Tesei A**, Cortesi M, Pignatta S, Arienti C, Dondio GM, Bigogno C, Malacrida A, Miloso M, Meregalli C, Chiorazzi A, Carozzi V, Cavaletti G, Rui M, Marra A, Rossi D, Collina S. Anti-tumor Efficacy Assessment of the Sigma Receptor Pan Modulator RC-106. A Promising Therapeutic Tool for Pancreatic Cancer. *Front Pharmacol*. 2019 May 14; 10:490.
23. Zanoni M, Pignatta S, Arienti C, Bonafè M, **Tesei A**. Anticancer drug discovery using multicellular tumor spheroid models. *Expert Opin Drug Discov*. 2019 Mar; 14(3):289-301.
24. Storci G, De Carolis S, Papi A, Bacalini MG, Gensous N, Marasco E, **Tesei A**, Fabbri F, Arienti C, Zanoni M, Sarnelli A, Santi S, Olivieri F, Mensà E, Latini S, Ferracin M, Salvioli S, Garagnani P, Franceschi C, Bonafè M. Genomic stability, anti-inflammatory phenotype, and up-regulation of the RNaseH2 in cells from centenarians. *Cell Death Differ*. 2019 Jan 8.
25. Carragher N, Piccinini F, **Tesei A**, Trask Jr OJ, Bickle M, Horvath P. Concerns, challenges and promises of high-content analysis of 3D cellular models. *Nat Rev Drug Discov*. 2018 Aug;17(8):606.
26. **Tesei A**, Cortesi M, Zamagni A, Arienti C, Pignatta S, Zanoni M, Paolillo M, Curti M, Rui M, Rossi D, Collina S. Sigma receptors as endoplasmic reticulum stress "gatekeepers" and their modulators as emerging new weapons in the fight against cancer. *Frontiers in Pharmacology* 2018. *Front Pharmacol*. 2018 Jul 10;9:711.
27. Arienti C, Pignatta S, Zanoni M, Cortesi M, Zamagni A, Piccinini F, **Tesei A**. Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down. *J Vis Exp*. 2017 Dec 11;(130).
28. Cortesi, M., Pasini, A., Tesei, A., Giordano, E. AIM: A computational tool for the automatic quantification of scratch wound healing assays (2017) *Applied Sciences (Switzerland)*, 7 (12), art. no. 1237 .
29. Piccinini F, **Tesei A**, Zanoni M, Bevilacqua A. ReViMS: Software tool for estimating the volumes of 3-D multicellular spheroids imaged using a light sheet fluorescence microscope. *Biotechniques*. 2017 Nov 1;63(5):227-229.
30. Parisi E, Romeo A, Sarnelli A, Ghigi G, Bellia SR, Neri E, Micheletti S, Dipalma B, Arpa D, Furini G, Burgio MA, Genestreti G, Gurioli C, Sanna S, Bovolato P, Rea F, Storme G, Scarpi E, Arienti C, **Tesei A**, Polico R. High dose irradiation after pleurectomy/decortication or biopsy for pleural mesothelioma treatment. *Cancer Radiother*. 2017 Dec;21(8):766-773.
31. Carloni S, Gallerani G, **Tesei A**, Scarpi E, Verdecchia GM, Virzi S, Fabbri F, Arienti C. DNA ploidy and S-phase fraction analysis in peritoneal carcinomatosis from ovarian cancer: correlation with clinical pathological factors and response to chemotherapy. *Onco Targets Ther*. 2017 Sep 20;10:4657-4664.
32. De Carolis S, Pellegrini A, Santini D, Ceccarelli C, Leo A, Alessandrini F, Arienti C, Pignatta S, **Tesei A**, Mantovani V, Zamagni C, Taffurelli M, Sansone P, Bonafè M, Cricca M. Liquid biopsy in the diagnosis of HPV DNA in breast lesions. *Future Microbiol*. 2017 Oct 4.
33. Ferroni C, Pepe A, Kim YS, Lee S, Guerrini A, Parenti MD, **Tesei A**, Zamagni A, Cortesi M, Zaffaroni N, De Cesare M, Beretta GL, Trepel JB, Malhotra SV, Varchi G. 1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment. *J Med Chem*. 2017 Apr 13;60(7):3082-3093.
34. Piccinini, F., **Tesei A**, Arienti, C., Bevilacqua, A. Cell Counting and Viability Assessment of 2D and 3D Cell Cultures: Expected Reliability of the Trypan Blue Assay. (2017) *Biological Procedures Online*, 19 (1), art. no. 8.

35. Collina S, Bignardi E, Rui M, Rossi D, Gaggeri R, Zamagni A, Cortesi M, **Tesei A**. Are sigma modulators an effective opportunity for cancer treatment? A patent overview (1996-2016). *Expert Opin Ther Pat*. 2017 Jan 13:1-14.
36. Rui M, Rossi D, Marra A, Paolillo M, Schinelli S, Curti D, **Tesei A**, Cortesi M, Zamagni A, Laurini E, Pricl S, Schepmann D, Wünsch B, Urban E, Pace V, Collina S. Synthesis and biological evaluation of new aryl-alkyl(alkenyl)-4-benzylpiperidines, novel Sigma Receptor (SR) modulators, as potential anticancer-agents. *Eur J Med Chem*. 2016 Aug 31;124:649-665.
37. Piccinini F, **Tesei A**, Bevilacqua A. Single-image based methods used for non-invasive volume estimation of cancer spheroids: a practical assessing approach based on entry-level equipment. *Comput Methods Programs Biomed*. 2016 Oct;135:51-60
38. Arienti C, Zanoni M, Pignatta S, Del Rio A, Carloni S, Tebaldi M, Tedaldi G, **Tesei A**. Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer. *Oncotarget*. 2016 Feb 22. doi: 10.18632/oncotarget.7575.
39. Zanoni M, Piccinini F, Arienti C, Zamagni A, Santi S, Polico R, Bevilacqua A, **Tesei A**. 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained. *Scientific Reports*, 11January 2016.
40. De Carolis S, Bertoni S, Nati M, D'Anello L, Papi A, **Tesei A**, Cricca M, Bonafé M. Carbonic anhydrase 9 mRNA/microRNA34a interplay in hypoxic human mammospheres. *J Cell Physiol*. 2015 Nov 10. doi: 10.1002/jcp.25245.
41. Giustarini D, Galvagni F, **Tesei A**, Farolfi A, Zanoni M, Pignatta S, Milzani A, Marone IM, Dalle-Donne I, Nassini R, Rossi R. Glutathione, glutathione disulfide, and S-glutathionylated proteins in cell cultures. *Free Radic Biol Med*. 2015 Dec;89:972-81. doi: 10.1016/j.freeradbiomed.2015.10.41
42. Pasini A, Delmonte A, **Tesei A**, Calistri D, Giordano E. Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results. *Drugs*. 2015 Oct;75(15):1757-71. doi: 10.1007/s40265-015-0461-3.
43. Pignatta S, Orienti O, Falconi M, Teti G, Arienti A, Medri L, Zanoni M, Carloni S, Zoli W, Amadori D, **Tesei A**. Albumin nanocapsules containing fenretinide: pre-clinical evaluation of cytotoxic activity in experimental models of human non-small cell lung cancer. *Nanomedicine*. 2015 Feb;11(2):263-73. doi: 10.1016/j.nano.2014.10.004.
44. Piccinini F, **Tesei A**, Zoli W, Bevilacqua A. Cancer multicellular spheroids: volume assessment from a single 2D projection.. *Comput Methods Programs Biomed*. 2015 Feb;118(2):95-106. doi: 10.1016/j.cmpb.2014.12.003
45. Piccinini F, **Tesei A**, Paganelli G, Zoli W, Bevilacqua A. Improving reliability of live/dead cell counting through automated image mosaicing. *Computer Methods and Programs in Biomedicine*, DOI: 10.1016/j.cmpb.2014.09.004, September 2014.
46. Gibellini L, Pinti M, Boraldi F, Giorgio V, Bernardi P, Bartolomeo R, Nasi M, De Biasi S, Missiroli S, Carnevale G, Losi L, **Tesei A**, Pinton P, Quaglini D, Cossarizza A. Silencing of mitochondrial Lon protease deeply impairs mitochondrial proteome and function in colon cancer cells. *FASEB J*. 2014 Aug 25. pii: fj.14-255869.
47. Piccinini, F., Tesei, A., Zoli, W., Bevilacqua, A. Image processing method for 3D volume rendering from one 2D projection: Application to Cancer spheroids (2014) 2014 4th International Conference on Image Processing Theory, Tools and Applications, IPTA 2014, art.no. 7001940.
48. Guerrini A, **Tesei A**, Ferroni C, Paganelli G, Zamagni A, Carloni S, Di Donato M, Castoria G, Leonetti C, Porru M, De Cesare M, Zaffaroni N, Beretta GL, Del Rio A, Varchi G. A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides. *J Med Chem*. 2014 Sep 11;57(17):7263-79.
49. Durante S, Orienti I, Teti G, Salvatore V, Focaroli S, **Tesei A**, Pignatta S, Falconi M. Anti-tumor activity of fenretinide complexed with human serum albumin in lung cancer xenograft mouse model. *Oncotarget*. 2014 Jul 15;5(13):4811-20
50. Arienti C, Zoli W, Pignatta S, Carloni S, Paganelli G, Ulivi P, Romeo A, Menghi E, Sarnelli A, Medri L, Polico R, Silvestrini R, **Tesei A**. Efficacy of Different Sequences of Radio- and Chemotherapy in Experimental Models of Human Melanoma. *J Cell Physiol*. 2014 Mar 4. doi: 10.1002/jcp.24598.
51. Pignatta S, Arienti C, Zoli W, Di Donato M, Castoria G, Gabucci E, Casadio V, Falconi M, De Giorgi U, Silvestrini R, **Tesei A**. Prolonged exposure to (R)-bicalutamide generates a LNCaP subclone with alteration of mitochondrial genome. *Mol Cell Endocrinol*. 2014 Jan 25;382(1):314-24.
52. **Tesei A**, Sarnelli A, Arienti C, Menghi E, Medri L, Gabucci E, Pignatta S, Falconi M, Silvestrini R, Zoli W, D'Errico V, Romeo A, Parisi E, Polico R. In vitro irradiation system for radiobiological experiments. *Radiat Oncol*. 2013 Nov 1;8:257.

53. **Tesei A**, Leonetti C, Di Donato M, Gabucci E, Porru M, Varchi G, Guerrini A, Amadori D, Arienti C, Pignatta S, Paganelli G, Caraglia M, Castoria G, Zoli W. Effect of small molecules modulating androgen receptor (SARMs) in human prostate cancer models. *PLoS One*. 2013 May 8;8(5):e62657.
54. Pasini A, Paganelli G, **Tesei A**, Zoli W, Giordano E, Calistri D. Specific Biomarkers Are Associated with Docetaxel and Gemcitabine-Resistant NSCLC Cell Lines. *Transl Oncol*. 2012 Dec;5(6):461-8.
55. Arienti C, **Tesei A**, Verdecchia GM, Framarini M, Virzi S, Grassi A, Scarpi E, Turci L, Silvestrini R, Amadori D, Zoli W. Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer. *Clin Colorectal Cancer*. 2013 Jun;12(2):122-7.
56. Arienti C, **Tesei A**, Carloni S, Ulivi P, Romeo A, Ghigi G, Menghi E, Sarnelli A, Parisi E, Silvestrini R, Zoli W. SLUG silencing increases radiosensitivity of melanoma cells in vitro. *Cell Oncol (Dordr)*. 2013 Apr;36(2):131-9.
57. Varchi G., Guerrini A, Di Donato M., **Tesei A**., Brigliadori G., Bertucci C, Castoria G. Non-steroidal androgen receptor ligands: versatile syntheses and biological data. *ACS Med. Chem. Lett*. 2012, 3, 454–458, 2012; dx.doi.org/10.1021/ml3000269
58. Ibrahim T, Mercatali L, Sacanna E, **Tesei A**, Carloni S, Ulivi P, Liverani C, Fabbri F, Zanoni M, Zoli W, Amadori D. Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid. *Cancer Cell Int*. 2012 Nov 22;12(1):48. doi: 10.1186/1475-2867-12-48.
59. Piccinini F, **Tesei A**, Zoli W, Bevilacqua A. Extended depth of focus in optical microscopy: assessment of existing methods and a new proposal. *Microsc Res Tech*. 2012 Nov;75(11):1582-92. doi: 10.1002/jemt.22104..
60. Ulivi P, Romagnoli M, Chiadini E, Casoni GL, Capelli L, Gurioli C, Zoli W, Saragoni L, Dubini A, **Tesei A**, Amadori D, Poletti V. Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patients. *Int J Oncol*. 2012 Jul;41(1):147-52. doi: 10.3892/ijo.2012.1432. Epub 2012 Apr 10.
61. **Tesei A**, Brigliadori G, Carloni S, Fabbri F, Ulivi P, Arienti C, Sparatore A, Del Soldato P, Pasini A, Amadori D, Silvestrini R, Zoli W. Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity. *J Cell Physiol*. 2012 Oct;227(10):3389-96. doi: 10.1002/jcp.24039
62. Arienti C, **Tesei A**, Verdecchia GM, Framarini M, Virzi S, Grassi A, Scarpi E, Turci L, Silvestrini R, Amadori D, Zoli W. Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy. *J Transl Med*. 2011 Jun 20;9:94.
63. Fabbri F, Zoli W, Carloni S, Ulivi P, Arienti C, Brigliadori G, Montanari M, **Tesei A**, Silvestrini R, Amadori D. Activity of different anthracycline formulations in hormone-refractory prostate cancer cell lines: role of Golgi apparatus. *J Cell Physiol*. 2011 Nov;226(11):3035-42.
64. Ulivi P, Arienti C, Zoli W, Scarsella M, Carloni S, Fabbri F, **Tesei A**, Chiadini E, Orlandi A, Passeri D, Zupi G, Milandri C, Silvestrini R, Amadori D, Leonetti C. In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells. *Curr Cancer Drug Targets*. 2010 Nov 1;10(6):600-10.
65. **Tesei A**, Leonetti C, Zupi G, Scarsella M, Brigliadori G, Ulivi P, Fabbri F, Arienti C, Amadori D, Passardi A, Silvestrini R, Zoli W. Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models. *J Cell Mol Med*. 2009 Dec 8.
66. Fabbri F, Brigliadori G, Carloni S, Ulivi P, **Tesei A**, Silvestrini R, Amadori D, Zoli W. Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression. *Prostate*. 2010 Feb 1;70(2):219-27.
67. Vannini I, Zoli W, Fabbri F, Ulivi P, **Tesei A**, Carloni S, Brigliadori G, Amadori D. Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines. *Anticancer Drugs*. 2009 Nov;20(10):918-25.
68. Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, **Tesei A**, Vannini I, Silvestrini R, Zoli W. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. *J Cell Physiol*. 2009 Jul;220(1):214-2.

69. **Tesei A**, Zoli W, Arienti C, Storci G, Granato AM, Pasquinelli G, Valente S, Orrico C, Rosetti M, Vannini I, Dubini A, Dell'Amore D, Amadori D, Bonafè M. Isolation of stem/progenitor cells from normal lung tissue of adult humans. *Cell Prolif.* 2009 Jun;42(3):298-308.
70. Fabbri F, Amadori D, Carloni S, Briigliadori G, **Tesei A**, Ulivi P, Rosetti M, Vannini I, Arienti C, Zoli W, Silvestrini R. Mitotic Catastrophe and Apoptosis Induced by Docetaxel in Hormone-Refractory Prostate Cancer Cells. *Cell Physiol.* 2008 Nov;217(2):494-501.
71. Vannini I, Zoli W, **Tesei A**, Rosetti M, Sansone P, Storci G, Passardi A, Massa I, Ricci M, Gusolfino D, Fabbri F, Ulivi P, Briigliadori G, Amadori D, Bonafè M. Role of p53 codon 72 arginine allele in cell survival in vitro and in the clinical outcome of patients with advanced breast cancer. *Tumour Biol.* 2008;29(3):145-51. Epub 2008 Jul 9
72. Fabbri F, Briigliadori G, Carloni S, Ulivi P, Vannini I, **Tesei A**, Silvestrini R, Amadori D, Zoli W. Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. *J Transl Med.* 2008 Aug 8;6:43.
73. **Tesei A**, Zoli W, Fabbri F, Leonetti C, Rosetti M, Bolla M, Amadori D, Silvestrini R. NCX 4040, an NO-donating acetylsalicylic acid derivative: Efficacy and mechanisms of action in cancer cells. *Nitric Oxide.* 2008 Apr 22.
74. Rosetti M, Frasnelli M, Fabbri F, Arienti C, Vannini I, **Tesei A**, Zoli W, Conti M. Pro-apoptotic activity of cyclopentenone in cancer cells. *Anticancer Res.* 2008 Jan-Feb;28(1A):315-20.
75. Arienti C, **Tesei A**, Ravaioli A, Ratta M, Carloni S, Mangianti S, Ulivi P, Nicoletti S, Amadori D, Zoli W. Activity of lipoplatin in tumor and in normal cells in vitro. *Anticancer Drugs.* 2008 Nov;19(10):983-90.
76. Passardi A, Maltoni R, Milandri C, Ceconetto L, Massa I, Zoli W, **Tesei A**, Fabbri F, Nanni O, Amadori D. Phase I study of paclitaxel and uracil plus tegafur combination in patients with pretreated metastatic breast cancer: drug sequencing based on preclinical modelling studies. *Oncology.* 2007;72(1-2):118-24. Epub 2007 Nov 15.
77. **Tesei A**, Rosetti M, Ulivi P, Fabbri F, Medri L, Vannini I, Bolla M, Amadori D, Zoli W. Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines. *J Transl Med.* 2007 Oct 30;5:52.
78. De Marco C, Zaffaroni N, Comijn E, **Tesei A**, Zoli W, Peters GJ. Comparative evaluation of C1311 cytotoxic activity and interference with cell cycle progression in a panel of human solid tumour and leukaemia cell lines. *Int J Oncol.* 2007 Oct;31(4):907-13.
79. Rosetti M, Zoli W, **Tesei A**, Ulivi P, Fabbri F, Vannini I, Briigliadori G, Granato A M, Amadori D, Silvestrini R. Iressa Strengthens the Cytotoxic Effect of Docetaxel in NSCLC Models that Harbor Specific Molecular Characteristics. *Cell Physiol.* 2007 Sep;212(3):710-6.
80. Vannini I, Bonafè M, **Tesei A**, Rosetti M, Fabbri F, Storci G, Ulivi P, Briigliadori G, Amadori D and Zoli W. Short interfering RNA directed against the Slug gene increases cell death induction in human melanoma cell lines exposed to cisplatin and fotemustine. *Cell Oncol.* 2007;29(4):279-87.
81. Leonetti C, Scarsella M, Zupi G, Zoli W, Amadori D, Medri L, Fabbri F, Rosetti M, Ulivi P, Ceconetto L, Bolla M, **Tesei A**. Efficacy of a nitric oxide-releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts. *Mol Cancer Ther.* 2006 Apr;5(4):919-26.
82. Rosetti M, **Tesei A**, Ulivi P, Fabbri F, Vannini I, Briigliadori G, Amadori D, Bolla M, Zoli W. Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines. *Apoptosis*, 2006 .
83. Ulivi P, Zoli W, Calistri D, Fabbri F, **Tesei A**, Rosetti M, Mengozzi M, Amadori D. p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. *J Cell Physiol.* 2006 Mar;206(3):611-5.
84. Rosetti M, Frasnelli M, **Tesei A**, Zoli W, Conti M. Cytotoxicity of different selective serotonin reuptake inhibitors (SSRIs) against cancer cells. *J Exp Ther Oncol.* 2006;6(1):23-9.
85. **Tesei A**, Ulivi P, Fabbri F, Rosetti M, Leonetti C, Scarsella M, Zupi G, Amadori D, Bolla M, Zoli W. In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines. *J Transl Med*, 2005, Feb 3;3(1):7.

86. Ulivi P, Zoli W, Fabbri F, Brigladori G, Ricotti L, **Tesei A**, Rosetti M, De Cesare M, Beretta GI, Corna E, Supino R, Zunino F. Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models. *Neoplasia*, 2005, 7:152-161.
87. Ibrahim T, Zoli W, Frassinetti GI, **Tesei A**, Colantonio I, Monti M, Amadori D. Innovative sequence of docetaxel-gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study. *Lung Cancer*, 2005, 47:261-267.
88. Fabbri F, Brigladori G, Ulivi P, **Tesei A**, Vannini I, Rosetti M, Bravaccini S, Amadori D, Bolla M, And Zoli W. Pro- apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells. *Apoptosis*, 2005, Oct;10(5):1095-103.
89. Zoli W, Ulivi P, **Tesei A**, Fabbri F, Rosetti M, Maltoni R, Casadei Giunchi D, Ricotti L, Brigladori G, Vannini I, Amadori D. Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines. *Breast Cancer Research*, 2005;7(5):R681-9.
90. Rosetti M, **Tesei A**, Ulivi P, Fabbri F, Vannini I, Brigladori G, Granato A, Amadori D, Zoli W. Modulation of drug cytotoxicity by iressa (ZD 1839) in pancreatic cancer cell lines. *Cancer Biol Ther*, 2005 Oct;4(10):1089-95.
91. Zoli W, Ricotti L, **Tesei A**, Ulivi P, Campani Ag, Fabbri F, Gunelli R, Frassinetti GI, Amadori D. Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro. *Clin Cancer Res*, 2004, 10: 1500-1507.
92. **Tesei A**, Ricotti L, Ulivi P, Medri L, Amadori D, Zoli W. NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines. *Int J Oncol*. 2003, 22: 1297-1302.
93. Ricotti L, **Tesei A**, De Paola F, Milandri C, Amadori D, Frassinetti GI, Ulivi P, Zoli W. Potentiation of antiproliferative drug activity by lomidamine in hepatocellular carcinoma cells. *J Chemother*, 2003, 15: 480-487.
94. Ricotti L, **Tesei A**, De Paola F, Ulivi P, Frassinetti GL, Milandri C, Amadori D, Zoli W. In vitro schedule-dependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines. *Clin Cancer Res*, 2003, 9:900-905.
95. **Tesei A**, Ricotti L De Paola F, Amadori D, Frassinetti GL, Zoli W. In vitro schedule-dependent interactions between the multitargeted antifolate ly231514 and gemcitabine in human colon adenocarcinoma cell lines. *Clin. Cancer Res*, 2002, 8: 233-239.
96. Zoli W, Barzanti F, Dal Susino M, De Paola F, **Tesei A**, Ricotti L, Padovani F, Reno F, Amadori D, Flow-cytometric determination of tumor cells in lymphonodes. *Oncology*, 2002, 62:128-135.
97. Zoli W, Ricotti L, **Tesei A**, Barzanti F, Amadori D. *In vitro* preclinical models for a rational design of chemotherapy combinations in human tumors. *Crit Rev Oncol Hematol*, 2001, 37: 69-82.
98. Barzanti F, Zoli W, Susino M, Ricotti L, **Tesei A**, Papa S, Reno F, Amadori D. Simultaneous determination of apoptosis and surface antigen expression in tumor adherent cells. *J Biol Regul Homeost Agents*, 2001, 15: 359-365.
99. **Tesei A**, Ricotti L, De Paola F, Casini-Raggi C, Barzanti F, Frassinetti GL, Zoli W. Lanreotide-induced modulation of 5-fluorouracil or mitomycin C cytotoxicity in human colon cancer cell lines: a preclinical study. *J Chemother*, 2000, 12: 421-430.
100. Ricotti L, Barzanti F, **Tesei A**, Amadori D, Gasperi-Campani A, Frassinetti GL, Zoli W. Combined 4-hydroxy-ifosfamide and vinorelbine treatment in established and primary human breast cell cultures. *Ann Oncol*, 2000, 11: 587-594.
101. Zoli W, Ricotti L, Dal Susino M, Barzanti F, Frassinetti GL, Folli S, **Tesei A**, Bacci F, Amadori D. Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer. *Br J Cancer*, 1999, 81(4):609-615.
102. Ricotti, L., Zoli, W., Barzanti, F., Dal Susino, M., Frassinetti, G.L., **Tesei, A.**, Casadei Giunchi, D., Amadori, D. Preclinical evaluation of the interaction among doxorubicin, paclitaxel and gemcitabine in human breast cancer cell line (1997) *Cell Proliferation*, 30 (10-12), p. 460.